Editorial

In vivo dosimetry (IVD) is an essential tool that contributes to the safety of radiotherapy treatments. This measurement of the dose in the presence of the patient allows errors to be detected so that their possible consequences can be alleviated.

The requirement that centres perform IVD (INCa authorisation criterion) involves “technically measurable beams”. However, the proportion of patients treated using beams of modulated intensity (IMRT or volumetric modulated arc therapy) continues to grow; this raises the question of the inadequacy of the “standard” method of dose measurement at a point.

This bulletin no. 5 invites you to discover the innovative solution of so-called in vivo “transit” dosimetry currently being implemented at the Curie Institute (75), the François Baclesse centre in Caen (14) and the Thiais (94) centre. You will also find an overview of the practice of standard IVD in France and several European countries, as well as feedback from the La Roche sur Yon (85) and Jean Bernard (72) centres, which have been practicing IVD for 4 and 6 years, respectively.

We hope you find it interesting!

The Editors

Contents

- Background ................................................ 3
- Key figures/Decoding ....................................... 4
- Radiotherapy centre experience ...................................... 5
- Steps for progress ...................................... 5 / 6
- Further reading ............................................ 7
The requirement for in vivo dosimetry (IVD) is one of the French National Cancer Institute (INCa) authorisation criteria for practicing external radiotherapy, an integral part of the system of authorisation for cancer treatment (2007 decree). This requirement was implemented in the framework of the French radiotherapy measures specified in 2007.

Approval criterion no. 15 stipulates: “In vivo dosimetry is to be performed for each technically measurable beam during the first or second irradiation session, as well as at each modification in the treatment”. In order to assist radiotherapy centres in observing this requirement as soon as possible and under the best possible conditions, the INCa financed equipment for radiotherapy centres in the private or public sector in the amount of € 3.1M in 2008.

The 2013 French radiotherapy observatory indicates that at the end of December 2012, all the centres that had responded (168/172) were equipped with in vivo dosimetry systems.

68% of the centres use IVD for all their treatments in which beams are technically measurable, with the share of non-technically measurable beams estimated at 21% on average. The most widespread equipment is that of direct readout type, 93% of which uses semiconductor diodes. Most centres have defined an action threshold at 5% discrepancy between the measured dose and the calculated dose.

The share of the centres using IVD systematically (100% implementation) has progressed by 41 points in 3 years (from 27% to 68% of the centres between 2009 and 2012).

IVD is considered good practice:
• in Belgium: the National Institute for Health and Disability Insurance (INAMI) reimburses four IVD sessions per patient;
• in the United Kingdom: in 2007, the Chief Medical Officer\(^1\) of England wrote in his report that IVD should be progressively introduced.

\(^1\) Chief Medical Officer (CMO) is the title used in several countries for the senior official designated as the head of medical services, most often at the national level. The position is occupied by a physician who serves as an adviser and directs a team of medical experts on questions of importance for public health.

A survey was conducted by ASN among 30 European countries (the 27 Member States in June 2013, Norway, Switzerland and Iceland). Twelve countries responded.

IVD is not mandatory for all beams in most European countries (Austria, Finland, Belgium, Germany, Greece, United Kingdom, Estonia, and Lithuania).

IVD has been mandatory in Sweden since 2000, in Denmark since 2001, in Norway since 2004, and is mandatory in the Czech Republic.

In Austria, IVD is mandatory only for total-body irradiation.

In Finland, quality assurance for treatment planning must include verification of each individual treatment plan using a procedure optimally independent of the treatment planning system. In addition, every total-body irradiation must include an in vivo dose measurement. Use of in vivo dosimetry is also recommended for other types of radiotherapy.

Figure 1. Variation of the percentage of centres that have implemented IVD as a function of the level of implementation (for technically measurable beams) (143 centres responding over four years; source, 2013 French Radiotherapy Observatory (to appear))
In the course of the five years 2008 to 2012, ASN received 1187 notifications of external radiotherapy events involving a patient. The error was detected using in vivo dosimetry in 18 of these. These significant radiation protection events (SRPE) were classified as level 0 or level 1 on the ASN-SFRO scale.”

"Note:
An error detected using in vivo dosimetry does not necessarily meet a criterion for notification as a significant radiation protection event.

If the error is detected sufficiently early, it can be quickly corrected and is not routinely subject to notification to ASN.

However, a notification of errors of interest on the initiative of a centre according to criterion 6 (see ASN guide no. 11) is relevant from the perspective of sharing experience.

Key figures

In the course of the five years 2008 to 2012, ASN received 1187 notifications of external radiotherapy events involving a patient. The error was detected using in vivo dosimetry in 18 of these. These significant radiation protection events (SRPE) were classified as level 0 or level 1 on the ASN-SFRO scale."
Steps for progress

1. Good practices

Recommendations of the working group with the contribution of Isabelle Buchheit, manager of medical physics at the Lorraine Institut de Cancérologie (The centre has been practicing IVD for 25 years).

Recommendations:

- Choose IVD tools and specify measurement protocols sufficiently simple and robust that they can be incorporated into a clinical routine.

- If the use of different types of irradiation beams justifies it, don’t rule out having several co-existing in vivo measurement systems in the department.

- Stay aware of the available technical solutions and plan for the investments necessary for acquisition of a new solution, subject to having the resources necessary for incorporating it into the department.

- When implementing new external radiotherapy techniques, consider ahead of time the technical solutions that can be envisaged for in vivo dosimetry.

- In vivo dosimetry is a tool allowing an error to be detected, thus preventing it being reproduced systematically due to the Record and Verify systems. It is not a measurement of the absolute dose delivered to the patient.

- Quality controls of modulated beams before treatment using matrix detectors do not constitute in vivo dosimetry, as they are conducted in the absence of the patient.
2. Innovative initiatives

At the end of 2012, 25 dedicated accelerators (Cyberknife®, Novalis®, Tomotherapy®) were in use in France, as well as four Gamaknifes®. The rapidly increasing number of treatments performed using this apparatus use beams previously considered "not technically measurable". The innovative approach of so-called in-vivo "transit" dosimetry allows in vivo dosimetry to be extended to IMRT and volumetric modulated arc therapy. Studies are also underway on the same principle for tomotherapy.

Transit dosimetry is in particular being implemented at the Curie Institute (75), the François Baclesse centre in Caen (14) and the Thiais oncology centre (94).

Transit dosimetry

Usually used to check patient positioning, portal imagers (EPID) allow two-dimensional acquisition of the signal transmitted through the patient throughout the entire duration of irradiation. It is then possible to arrive at an estimate of the dose in the patient. The dose thus reconstructed can then be compared to the planned dose to validate the quality of the treatment delivered. This method has a certain number of advantages compared to the "standard" method (measurement of the dose at a point by placing a detector on the skin) and opens up a number of prospects with regard to strategies for validation of the dose delivered to the patient:

- **Ease of implementation.**
- **No additional time required at the treatment station**, allowing measurements to be repeated over several sessions.
- **Enrichment of the information** obtained through analysis of transmission images, on which the patient’s anatomical information can very often be used.
- **Possibility of analyses at several checkpoints** inside and outside the target volume.
- **Compatibility with comparison tools** such as the Gamma Index.

In volumetric modulated arc therapy

The Thiais (94) oncology centre has used transit dosimetry since July 2013 for treatments with the 3D conformal technique, with IMRT or by volumetric modulated arc therapy. Between July and September 2013, 1523 in vivo checks of the dose were performed using the portal imager. The results show good agreement between the dose calculated by TPS (DTPS) and the dose actually delivered to the patient (Dportal).

- **Of 1250 checks of treatments with the 3D conformal technique**, the average discrepancy between DTPS and Dportal was 0.6%, with a standard deviation (1 sigma) of 3.8% for calculation points located in the target volume and in organs at risk.

- **Of 249 treatments with volumetric modulated arc therapy**, the average discrepancy between DTPS and Dportal was 1.3%, with a standard deviation (1 sigma) of 3.0%, for all locations combined.

The greatest discrepancies (> 10%) were due to movements of the patient during irradiation, easily visible on the transit portal image.

These results are very encouraging, and show that use of portal images for IVD with reconstruction of the dose actually delivered to the patient is applicable for all techniques of irradiation with high-energy photons.

In tomotherapy

The François Baclesse centre in Caen (14) is currently testing a software that, starting from the signal collected by the detectors used for tomotherapy imaging, allows the dose to be reconstructed in a phantom, for pre-treatment verification of dosimetric plans, or in a patient, for 3D in vivo dosimetry.

The dose is retroprojected onto the tomodensitometric images to display the treatment plan dose distribution and then compared to the dose distribution measured at the output of the detectors. Currently available evaluation tools such as dose profiles, gamma index, and histograms allow the results to be analysed. One of the priorities in development of the software being tested is to be able to compare the patient output measurements for different sessions in order to monitor the progress of the treatment and decide whether it should be re-planned.

---

3 The concept of "not technically measurable" beams (see guide INCa 2008) designates beams or irradiation techniques for which point dose measurement is not suitable and not sufficiently representative of the dose delivered to the target volume. This is the case for example with IMRT, robotised treatments, helical tomotherapy and arc therapy treatments, and also beams for which the detector size is not suitable (stereotactic irradiations).
Further reading

In vivo dosimetry:

Authorisation criteria for the practice of external radiotherapy

Guide for the routine practice of in vivo dosimetry in external radiotherapy
written under the auspices of the National Cancer Institute (INCa) with the collaboration of the French Society of Medical Physics (SFPM) and the French Nuclear Safety Authority (ASN). October 2008.

In vivo electron beam dosimetry: recommendation of the SFPM (2010)
In August 2010, the ASN consulted the SFPM on the difficulties encountered in conducting in vivo electron beam dosimetry.


Previously published bulletins

N°1 Identification du patient [Patient identification] (March 2011)
N°2 La première séance "à blanc" [The verification session] (Nov. 2011)
N°3 Comment analyser vos événements significatifs de radioprotection? [How to analyse your significant radiation protection events?] (July 2012)
N°4 Quels événements déclarer à l'ASN? [Which events are to be declared to ASN? Available in French only] (April 2013)

To receive the bulletin by e-mail when it appears, register at:
http://www.asn.fr/index.php/bulletinradiotherapie/inscription


Other topics:

Patient safety
Paving the way for progress

ASN, January 2014